Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for glucocorticoid-resistant ICI-associated myocarditis (phase II)
ChiCTR2400083738Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in immune checkpoint inhibitor myocarditis, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: All-cause mortality within three months. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
03
Conditions
immune checkpoint inhibitor myocarditis
Beyond the preview
Go deeper on ChiCTR2400083738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083738.